Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LakeShore Biopharma ( (LSB) ) has provided an announcement.
On September 22, 2025, LakeShore Biopharma announced its transition from the Nasdaq Capital Market to the OTC Pink Open Market following a delisting determination due to non-compliance with Nasdaq’s minimum bid price requirement. This move does not affect the company’s business operations, and it remains committed to transparency with its stakeholders.
The most recent analyst rating on (LSB) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on LakeShore Biopharma stock, see the LSB Stock Forecast page.
Spark’s Take on LSB Stock
According to Spark, TipRanks’ AI Analyst, LSB is a Underperform.
LakeShore Biopharma’s overall stock score is primarily impacted by its weak financial performance and technical indicators. The company’s persistent losses and negative cash flows are significant concerns, compounded by bearish technical signals. The lack of profitability and dividend yield further detracts from its valuation appeal, making it a high-risk investment.
To see Spark’s full report on LSB stock, click here.
More about LakeShore Biopharma
LakeShore Biopharma, formerly known as YS Biopharma, is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics for infectious diseases and cancer. The company has developed a proprietary PIKA® immunomodulating technology platform and targets diseases such as Rabies, Hepatitis B, and Influenza. It operates in China, Singapore, and the Philippines.
Average Trading Volume: 323,444
Technical Sentiment Signal: Sell
Current Market Cap: $25.84M
Learn more about LSB stock on TipRanks’ Stock Analysis page.